Hemophilia a and b recombinant factor replacement therapy 5eu drug forecast and market analysis to 2

Hemophilia A and B Recombinant Factor Replacement Therapy 5EU Drug Forecast and Market Analysis to 2024 MarketResearchReports.Biz announces addition of new report" Hemophilia A and B Recombinant Factor Replacement Therapy 5EU Drug Forecast and Market Analysis to 2024

"to its database.

Congenital Hemophilia A and B are bleeding disorders that are caused by genetic Xlinked deficiencies in the blood clotting Factors VIII and IX, respectively. Hemophilia manifests as mild, moderate, or severe inability to form clots, depending upon the endogenous levels of circulating factor in an individual patient. The mainstay of treatment for hemophilia is to replace the missing FVIII or FIX, produced using plasmaderived or recombinant methods. Some patients develop inhibitors to FVIII or FIX treatment and need a bypassing agent, such as FVIIa, to resolve bleeds. Patients of hemophilia A or B often require lifelong treatment to prevent and control bleeding episodes, and this therefore represents a lucrative sales opportunity. The total market for recombinant hemophilia treatment in the 5EU is expected to grow from approximately $2.08 billion in 2014 to $2.36 billion in 2024. This growth will be driven by increasing rates of recombinant factor replacement therapies across the 5EU countries; in Italy and Spain in particular, where the current rate of prophylactic treatment is relatively low, an increasing proportion of adult patients are getting prophylactic treatments. GlobalData expects moderate and high rates of adoption of the longacting rFVIII and rFIX therapies, respectively, over the forecast period. However, GlobalDatas primary research indicates that the high annual cost of therapy is of great concern among physicians and regulators in Europe and therefore the opportunities for premium pricing for new therapies will be limited during the forecast period. View Report At :http://www.marketresearchreports.biz/analysis/759745 Scope Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for the top drugs in 5EU from 20142024. Analysis of the impact of key events as well the drivers and restraints affecting 5EU Hemophilia A and B market. Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B. Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and indepth analysis of drug performance Obtain sales forecast for drugs from 20142024 in 5EU. Download Sample copy of this Report at http://www.marketresearchreports.biz/sample/sample/759745 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Catalyst 2.2 Related Reports 2.3 Upcoming Related Reports 3 Disease Overview 3.1 Etiology and Pathophysiology 3.1.1 Etiology 3.1.2 Pathophysiology 3.1.3 Prognosis and Quality of Life 3.2 Symptoms 3.2.1 Hemophilia A and B 3.2.2 Inhibitors 4 Disease Management 4.1 Treatment Overview 4.1.1 Hemophilia A and B Diagnosis 4.1.2 Hemophilia A and B Treatment 4.1.3 Diagnosis of Inhibitors 4.1.4 Treatment of Inhibitors 4.2 France 4.2.1 Clinical Practice 4.3 Germany 4.3.1 Clinical Practice 4.4 Italy 4.4.1 Clinical Practice 4.5 Spain 4.5.1 Clinical Practice 4.6 UK 4.6.1 Clinical Practice 5 Competitive Assessment 5.1 Overview 5.2 Strategic Competitive Assessment 5.3 Product Profiles Hemophilia A 5.3.1 Advate (Octocog Alfa)

5.3.2 Kogenate FS/Helixate FS (Octocog Alfa) 5.3.3 Xyntha/ReFacto AF (Moroctocog Alfa) 5.3.4 Recombinate (Octocog Alfa) 5.3.5 Eloctate (Efmoroctocog Alfa) 5.3.6 NovoEight (Turoctocog Alfa) 5.3.7 Nuwiq (Simoctocog Alfa) 5.4 Product Profiles Hemophilia B 5.4.1 BeneFIX (Nonacog Alfa) Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports biz About us MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries. Contact Mr. Nachiket State Tower 90 Sate Street, Suite 700 Albany, NY 12207 Tel: +15186212074 Website: http://www.marketresearchreports.biz/ E: sales@marketresearchreports.biz

Turn static files into dynamic content formats.

Create a flipbook

Hemophilia a and b recombinant factor replacement therapy 5eu drug forecast and market analysis to 2

Published on Jul 25, 2016

roshani

GlobalData has released its pharma report, Hemophilia A and B Recombinant Factor Replacement Therapy - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Hemophilia A and B Market. The report identifies and analyses the key companies shaping and driving the global Hemophilia A and B market. The report provides insight into the competitive Hemophilia A and B landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalDatas team of industry experts.